Eli Lilly has anted up for its next big bet on a next-gen pain drug, buying Hydra assets
With its new CGRP migraine drug Emgality (galcanezumab) OK’d a few months ago and more late-stage work underway on lasmiditan and tanezumab, Eli Lilly’s pain group has selected its next shot at a next-gen drug.
The target is TRPA-1, one of the family of ion channel targets that has long been a focus at Hydra Biosciences, run by Russ Herndon. Hydra at one point had a collaboration on this way back in 2012 with Cubist, just before Cubist got bought out by Merck.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.